Royalty Pharma Financing Growth Alternative Traditional Biopharmaceutical Fundraising
Facing difficult traditional equity markets, biopharmaceutical companies are increasingly turning to royalty financing. This model provides them with upfront capital in exchange for a percentage of a drug's future revenue, avoiding equity dilution. For more info: https://www.zs.com/insights/royalty-financing-alternative-traditional-biopharma-fundraising
Facing difficult traditional equity markets, biopharmaceutical companies are increasingly turning to royalty financing. This model provides them with upfront capital in exchange for a percentage of a drug's future revenue, avoiding equity dilution. For more info: https://www.zs.com/insights/royalty-financing-alternative-traditional-biopharma-fundraising
Royalty Pharma Financing Growth Alternative Traditional Biopharmaceutical Fundraising
Facing difficult traditional equity markets, biopharmaceutical companies are increasingly turning to royalty financing. This model provides them with upfront capital in exchange for a percentage of a drug's future revenue, avoiding equity dilution. For more info: https://www.zs.com/insights/royalty-financing-alternative-traditional-biopharma-fundraising
0 Commentaires
0 Parts
95 Vue
0 Aperçu
English
Arabic
Spanish
Portuguese
Deutsch
Turkish
Dutch
Italiano
Russian
Romaian
Portuguese (Brazil)
Greek
